20
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T4258 | TLR7 agonist 2 | TLR7-agonist-1,TLR7-IN-1 | TLR |
TLR7 agonist 2 (TLR7-IN-1) is a specific and effective Toll-like Receptor 7 (TLR7) agonist (LEC=0.4 μM). | |||
T5561 | TLR7/8 agonist 1 dihydrochloride | TLR7/8 agonist-5d | TLR |
TLR7/8 agonist 1 dihydrochloride (TLR7/8 agonist-5d) is a TLR7/8 agonist which shows prominent immunostimulatory activities. | |||
T39669 | TLR7/8/9-IN-1 | TLR7/8/9-IN-1 | TLR |
TLR7/8/9-IN-1 is a potent inhibitor of Toll-like receptors 7/8/9 (TLR7/8/9) with an IC50 of 43 nM. | |||
T38078 | TLR7/8-IN-1 | TLR7/8-IN-1 | TLR |
TLR7/8-IN-1, a crystalline TLR7/TLR8 inhibitor, is a valuable compound for autoimmune disease research[1]. | |||
T13167 | TLR7/8 agonist 3 | TLR | |
TLR7/8 agonist 3 is a potent agonist of TLR7 and TLR8. | |||
T8316 | 1V209 | TLR7 agonist T7 | TLR |
1V209 (TLR7 agonist T7) is a Toll-like receptor 7 (TLR7) agonist and has anti-tumor effects. | |||
T39970 | TLR7/8 agonist 4 hydroxy-PEG10-acid hydrochloride | TLR7/8 agonist 4 hydroxy-PEG10-acid hydrochloride | |
TLR7/8 agonist 4 hydroxy-PEG10-acid hydrochloride (compound 9) is a drug-linker conjugate used in antibody-drug conjugates (ADCs) with high efficacy against tumors. It consists of TLR7/8 agonist 4, a potent TLR7/8 agonis... | |||
T38614 | TLR7 agonist 3 | ||
TLR7 agonist 3 (Compound 2), a potent activator of toll-like receptor 7 (TLR7), plays a critical role in initiating immune responses, positioning it as a promising target for immunomodulator development. | |||
T39968 | TLR7/8 agonist 4 hydroxy-PEG10-acid | TLR7/8 agonist 4 hydroxy-PEG10-acid | |
TLR7/8 agonist 4 hydroxy-PEG10-acid (compound 9) is a drug-linker conjugate employed in antibody-drug conjugates (ADC). This compound exhibits remarkable antitumor activity by utilizing TLR7/8 agonist 4, which acts as a ... | |||
T13168 | TLR7 agonist 1 | TLR | |
TLR7 agonist 1 is a selective and oral TLR7 agonist (IC50: 90 nM). | |||
T39969 | TLR7/8 agonist 4 TFA | ||
TLR7/8 agonist 4 TFA (compound 41) is a highly potent TLR7/8 agonist that exhibits significant anti-cancer activity. | |||
T72035 | TLR7/8/9 antagonist 2 | TLR | |
TLR7/8/9 antagonist 2 is an orally active and highly bioavailable vTLR7/8/9 antagonist. TLR7/8/9 antagonist 2 inhibits HEK/hTLR7, HEK/hTLR8 and HEK/hTLR9 with IC50s of 0.011 μM, 0.029 μM and 0,052 μM, respectively. TLR7/... | |||
T71108 | TLR7/8 agonist 1 | ||
TLR7/8 agonist 1 is a toll-like receptor ( TLR7 )/ TLR8 dual-agonistic imidazoquinoline. | |||
T62587 | TLR7 agonist 4 | ||
TLR7 agonist 4 (Compound 1.2) is a TLR7 agonist (EC50: 4.3 nM). | |||
TNU1350 | TLR7 agonist 13 | ||
TLR7 agonist 13 is a useful organic compound for research related to life sciences. The catalog number is TNU1350 and the CAS number is 2389988-70-7. | |||
T79751 | TLR7 agonist 16 | ||
TLR7 agonist 16 (compound 16d) is a potent activator of TLR7 with an EC50 value of 18 nM. It effectively triggers the activation of both mouse macrophages and human peripheral blood mononuclear cells (hPBMCs) at low-nano... | |||
T79750 | TLR7 agonist 15 | ||
TLR7 agonist 15 (compound 16b) is a potent activator of mouse macrophages and hPBMCs, demonstrating an EC50 of 18 nM. It induces robust responses at low-nanomolar concentrations [1]. | |||
T79749 | TLR7 agonist 14 | ||
Compound 17b, a TLR7 agonist also known as TLR7 agonist 14, exhibits high potency with an EC50 of 18 nM. It effectively activates mouse macrophages and human peripheral blood mononuclear cells (hPBMCs) at low-nanomolar c... | |||
T75213 | TLR7 agonist 12 | ||
TLR7 agonist 12 (example 20), a purine nucleoside analog, functions as a TLR7 agonist with broad antitumor activity, particularly against indolent lymphoid malignancies. Its anticancer mechanisms include DNA synthesis in... | |||
T79068 | TLR7/8 agonist 8 | ||
TLR7/8 agonist 8 (compound 24m) is a potent dual agonist for toll-like receptors 7 and 8 (TLR7/8), exhibiting half-maximal effective concentrations (EC50s) of 27 nM for human TLR7 (hTLR7) and 12 nM for human TLR8 (hTLR8)... |